LivaNova PLC (LIVN) & Its Peers Critical Review
LivaNova PLC (NASDAQ: LIVN) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its competitors? We will compare LivaNova PLC to similar businesses based on the strength of its dividends, risk, valuation, profitability, earnings, institutional ownership and analyst recommendations.
Institutional and Insider Ownership
82.3% of LivaNova PLC shares are held by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 0.3% of LivaNova PLC shares are held by company insiders. Comparatively, 11.4% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for LivaNova PLC and its competitors, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|LivaNova PLC Competitors||181||1145||2510||89||2.64|
LivaNova PLC presently has a consensus price target of $71.50, suggesting a potential downside of 2.46%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 8.47%. Given LivaNova PLC’s competitors stronger consensus rating and higher possible upside, analysts plainly believe LivaNova PLC has less favorable growth aspects than its competitors.
This table compares LivaNova PLC and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|LivaNova PLC Competitors||-128.33%||-36.98%||-10.17%|
Risk & Volatility
LivaNova PLC has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, LivaNova PLC’s competitors have a beta of 1.06, indicating that their average stock price is 6% more volatile than the S&P 500.
Valuation and Earnings
This table compares LivaNova PLC and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|LivaNova PLC||$1.21 billion||$191.69 million||128.60|
|LivaNova PLC Competitors||$827.23 million||$159.50 million||41.06|
LivaNova PLC has higher revenue and earnings than its competitors. LivaNova PLC is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
LivaNova PLC competitors beat LivaNova PLC on 7 of the 13 factors compared.
LivaNova PLC Company Profile
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Receive News & Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related companies with MarketBeat.com's FREE daily email newsletter.